vTv Therapeutics Inc
$ 34.29
-3.05%
10 Aug - close price
- Market Cap 139,310,000 USD
- Current Price $ 34.29
- High / Low $ 35.50 / 33.93
- Stock P/E N/A
- Book Value 7.25
- EPS -0.75
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.03 %
- ROE -0.01 %
- 52 Week High 44.00
- 52 Week Low 14.00
About
vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers, develops and sells candidates for orally administered small molecule drugs to meet unmet medical needs.
Analyst Target Price
$53.83
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-08-06 | 2026-05-13 | 2026-03-10 | 2025-11-06 | 2025-08-12 | 2025-05-15 | 2025-03-20 | 2024-11-12 | 2024-08-08 | 2024-05-09 | 2024-03-13 | 2023-11-09 |
| Reported EPS | -1.05 | 1.65 | -0.58 | -1.08 | -0.92 | -0.77 | -0.552 | -0.88 | -0.8089 | -1.1747 | -1.67 | -3.2 |
| Estimated EPS | -0.75 | 0.21 | -1.088 | -0.98 | -0.82 | -0.73 | -0.87 | -3.6 | None | None | -0.07 | -0.08 |
| Surprise | -0.3 | 1.44 | 0.508 | -0.1 | -0.1 | -0.04 | 0.318 | 2.72 | 0 | 0 | -1.6 | -3.12 |
| Surprise Percentage | -40% | 685.7143% | 46.6912% | -10.2041% | -12.1951% | -5.4795% | 36.5517% | 75.5556% | None% | None% | -2285.7143% | -3900% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: VTVT
2026-08-09 04:12:14
vTv Therapeutics (VTVT) stock rose 2.2% despite reporting widening losses and zero revenue in Q2 2026. The company's net loss roughly doubled year-on-year to US$13.054m, and basic EPS swung to a loss of US$1.05. Investors appear to be focusing on the company's clinical pipeline, particularly a Phase III program in type 1 diabetes, rather than its current financial performance.
2026-08-06 22:10:06
vTv Therapeutics Inc. has reported its financial results for the second quarter ended June 30, 2026, and provided a corporate update. The company expects to complete enrollment in its Phase 3 CATT1 trial for cadisegliatin, a treatment for type 1 diabetes, in Q3 2026 and plans to initiate a Phase 2a hybrid closed-loop trial by the end of 2026. vTv Therapeutics also announced it has sufficient cash to fund operations through the anticipated CATT1 topline data readout and will host a Key Opinion Leader event in Q4 2026 to discuss cadisegliatin's potential.
2026-08-06 11:40:07
vTv Therapeutics announced its Q2 2026 financial results, reporting a net loss of $13.1 million but maintaining sufficient cash to fund operations through the anticipated topline data readout of its Phase 3 CATT1 trial. Enrollment for the CATT1 trial, which evaluates cadisegliatin for type 1 diabetes, is expected to complete in Q3 2026, with a Phase 2a Hybrid CATT1 study commencing before the end of 2026. The company also plans to host a Key Opinion Leader event in Q4 2026 to discuss cadisegliatin's potential for T1D.
2026-08-06 11:40:07
vTv Therapeutics (Nasdaq: VTVT) announced its second-quarter 2026 financial results, highlighting that enrollment for its Phase 3 CATT1 trial for cadisegliatin, an oral therapy for type 1 diabetes, is expected to conclude in Q3 2026. The company plans to initiate a Phase 2a hybrid closed-loop trial (Hybrid CATT1) by the end of 2026 and expects its current cash reserves to fund operations through the anticipated CATT1 topline data readout. vTv Therapeutics also reported a net loss of $13.1 million for the quarter, compared to $6.0 million in the same period last year.
2026-07-29 22:31:34
Millennium-affiliated entities, including Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander, have filed an amended Schedule 13G/A disclosing their beneficial ownership in vTv Therapeutics Inc. (VTVT) Class A common stock. Integrated Core Strategies (US) LLC reports 6.3% ownership (249,027 shares), while Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander each report 6.9% ownership (269,874 shares), all with shared voting and dispositive power. The filing indicates these securities are held by entities controlled by Millennium and its related managers.
2026-07-26 04:42:12
This article provides a revenue breakdown for vTv Therapeutics, Inc. Class A (SWB:5VT0) listed on the Stuttgart Stock Exchange. It indicates fundamental and statistical information, including statements, dividends, earnings, and segment performance. The content is presented without specific financial figures, focusing on the available categories for financial analysis.
